Mezigdomide (MEZI) in novel combinations effectively reactivates immune system in patients with relapsed/refractory multiple myeloma (RRMM) including those after T-cell-redirecting therapies (TCRT)
Kurtova, A. Santucci-Pereira, J. Risueño, A. Takhar, M. Costa, L. Schjesvold, F. Popat, R. Siegel, D. Hartley-Brown, M. Usmani, S.
Kurtova, A.
Santucci-Pereira, J.
Risueño, A.
Takhar, M.
Costa, L.
Schjesvold, F.
Popat, R.
Siegel, D.
Hartley-Brown, M.
Usmani, S.
Citations
Altmetric:
Abstract
Authors
Description
Date
2025
Publisher
Collections
Keywords
Type
Meetings and Proceedings
Citation
Kurtova A, Santucci-Pereira J, Risueño A, Takhar M, Costa L, Schjesvold F, et al. Mezigdomide (MEZI) in novel combinations effectively reactivates immune system in patients with relapsed/refractory multiple myeloma (RRMM) including those after T-cell-redirecting therapies (TCRT). CLINICAL LYMPHOMA MYELOMA & LEUKEMIA. 2025 SEP;25. PubMed PMID: WOS:001592901300066. English.